A clinical experience of single agent bevacizumab in relapsing ovarian cancer
Authors:
- Laure ChauvenetLCLaure Chauvenet
- Jean-Marie TigaudJTJean-Marie Tigaud
- Jean ChidiacJCJean Chidiac
- Eric Pujade LauraineELEric Pujade Lauraine
- Jerome AlexandreJAJerome Alexandre
- 1 June 2013
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 129 (3) , 459-462
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian CancerNew England Journal of Medicine, 2011
- A Phase 3 Trial of Bevacizumab in Ovarian CancerNew England Journal of Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Expression of Angiogenesis-Related Genes and Progression of Human Ovarian Carcinomas in Nude MiceJNCI: Journal of the National Cancer Institute, 1998
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI: Journal of the National Cancer Institute, 1990
- ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESISJournal of Experimental Medicine, 1971